Amna Ibrahim
Researcher Next ID · RN-020264
Researcher · Medicine
Banī Suwayf, Kenya
- Works count
- 101
- Citation count
- 6,679
- H-index
- 38
- i10-index
- 53
Research interests
Publications
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors
Clinical Cancer Research · 2022 · 10.1158/1078-0432.ccr-22-1054
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease–Associated Tumors
Clinical Cancer Research · 2022 · 10.1158/1078-0432.ccr-22-1054
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Cancer Research · 2022 · 10.1158/1078-0432.ccr-22-2875
External control arms in oncology: current use and future directions
Annals of Oncology · 2022 · 10.1016/j.annonc.2021.12.015
External control arms in oncology: current use and future directions
Annals of Oncology · 2022 · 10.1016/j.annonc.2021.12.015
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Clinical Cancer Research · 2020 · 10.1158/1078-0432.ccr-20-2275
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Clinical Cancer Research · 2020 · 10.1158/1078-0432.ccr-19-3545
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1
Clinical Cancer Research · 2020 · 10.1158/1078-0432.ccr-19-3545
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
Clinical Cancer Research · 2020 · 10.1158/1078-0432.ccr-20-2275
Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody
Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.00318
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30804-6
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-18-0042
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy
The Oncologist · 2018 · 10.1634/theoncologist.2018-0084
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
Clinical Cancer Research · 2018 · 10.1158/1078-0432.ccr-18-0042
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
The Oncologist · 2017 · 10.1634/theoncologist.2016-0476
FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
The Oncologist · 2017 · 10.1634/theoncologist.2016-0476
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-15-1185
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-15-0887
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
Clinical Cancer Research · 2014 · 10.1158/1078-0432.ccr-14-0776
First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
Clinical Cancer Research · 2014 · 10.1158/1078-0432.ccr-14-1268
FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
Clinical Cancer Research · 2014 · https://doi.org/10.1158/1078-0432.ccr-14-0012
First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
Clinical Cancer Research · 2014 · 10.1158/1078-0432.ccr-14-1268
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
Clinical Cancer Research · 2013 · 10.1158/1078-0432.ccr-13-2665
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
Clinical Cancer Research · 2013 · 10.1158/1078-0432.ccr-13-2665
Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary
Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-12-0411
Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary
Clinical Cancer Research · 2012 · 10.1158/1078-0432.ccr-12-0411
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
The Oncologist · 2010 · 10.1634/theoncologist.2009-0178
FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2
The Oncologist · 2008 · https://doi.org/10.1634/theoncologist.2008-0816
FDA Drug Approval Summaries: Oxaliplatin
The Oncologist · 2004 · 10.1634/theoncologist.9-1-8
FDA Drug Approval Summaries: Oxaliplatin
The Oncologist · 2004 · 10.1634/theoncologist.9-1-8
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
PubMed · 2003
Current projects
No projects listed.